Web Research
Web Research
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
The Bottom Line from the Web
The web's load-bearing fact — under-emphasized in filings — is the EQT promoter sell-down: since IPO (Nov 2024) the sponsor has stepped from 100% to 50.95% across two Offer-for-Sale events at progressively higher prices, while the stock is down ~21% YTD with 100% of remaining promoter shares pledged. Layered on top: FY26 reported revenue growth of 29% is ~10pp overstated by FX and BroadPath (organic constant-currency was 15.0% FY, 19.4% Q4), and Capgemini–WNS (16.3x EV/EBITDA) sets a strategic ceiling that Sagility (10.8x) is already approaching. The forensic file is clean — no short-seller, no SEBI/SEC probe, no auditor qualifications — but the Q3 FY26 transcript shows BroadPath cross-sell stalled and the CFO seat has changed twice in six months without explanation.
Top web-only findings investors must absorb: (1) Promoter EQT has reduced stake from 82.4% → 50.95% in 12 months and 100% of remaining promoter shares are pledged; (2) FY26 organic CC growth was only ~15% versus the 29% INR headline; (3) Capgemini–WNS sets a 16.3x EV/EBITDA strategic ceiling; (4) CFO has been replaced twice between Nov 2025 and Q4 FY26.
What Matters Most
Promoter stake (Mar'26)
Consensus TP ($)
FY26 Adj EBITDA margin
FY26 organic CC growth
1. EQT promoter sell-down has been the dominant capital-markets event — and 100% of remaining promoter shares are pledged
Sagility B.V. (EQT Private Capital Asia) has reduced its stake from 82.39% (Mar 2025) to 50.95% (Mar 2026) via two Offer-for-Sale rounds. MarketsMojo separately flags that 100% of the remaining promoter shares are pledged — an unusual disclosure for an EQT portfolio company and a material governance flag.
The first OFS (May 27–28, 2025) disposed 70.3 crore shares (15.02% of equity) at a $0.44 floor, raising ~$311M. The second (Nov 14, 2025) was a block deal of 76.9 crore shares (16.4%) at $0.53, raising $407M — five global/domestic institutions (including Unifi Capital and ICICI Prudential) absorbed 8.6%. Promoter stake now sits exactly at the SEBI minimum public float comfort buffer; further reduction is discretionary, not mandated. (Sources: angelone.in 17 Nov 2025; moneycontrol.com block-deal coverage; trendlyne.com SAST filings; smartkarma.com lockup analysis 6 May 2025; marketsmojo.com — pledge disclosure)
2. FY26 headline growth is materially flattered by FX and BroadPath
Reported FY26 revenue was $767M, +29.1% YoY in INR. Organic constant-currency growth was only 15.0% for FY26 and 19.4% in Q4 FY26 — BroadPath contributed ~9 pp of INR growth and INR depreciation roughly 5 pp of the remaining gap.
CNBC TV18 (12 May 2026) and the Q3 FY26 transcript both flag the organic CC vs reported gap. Quartr's FY26 summary credits "declining finance costs and higher forex gains" for the 39.5% adj. PAT growth. Top-5 client growth was 11.7% YoY in FY26 — consistent with the diversification narrative but confirming the headline is doing heavy lifting. (Sources: cnbctv18.com 12 May 2026; quartr.com FY26 summary; tradealone.com FY26 review.)
3. Capgemini–WNS sets a hard valuation ceiling — Sagility is already three-quarters of the way there
Capgemini's $3.3bn acquisition of WNS (announced 7 Jul 2025) implies 16.3x EV/EBITDA and 2.5x EV/Revenue — the strategic-takeout multiple for the BPS pure-play category. Sagility currently trades at 10.7–10.8x EV/EBITDA and 2.6–2.7x EV/Revenue — already at the WNS revenue multiple, with a one-turn EBITDA-multiple gap left to close.
Everest Group's Nov 2025 note framed the deal as creating "a global leader in Agentic AI-powered Intelligent Operations" — supporting the AI-led-services thesis Sagility is selling, while bounding the strategic premium. Among listed Indian peers, Inventurus Knowledge Solutions trades at ~39x trailing P/E and >18x EV/EBITDA; Sagility's ~20x P/E reflects a discount for promoter overhang and concentration. (Sources: everestgrp.com blog 16 Nov 2025; multiples.vc 29 May 2026; groww.in peer comparison; capgemini.com press release.)
4. CFO seat has turned over twice in six months — neither transition was explained on calls
Sarvabhouman Doraiswamy Srinivasan resigned 15 Nov 2025 "for personal reasons" after joining at carve-out close in Jan 2022. Abhishek Kayan was appointed Deputy CFO. By Q4 FY26 (12 May 2026) Yahoo Finance lists Srinivas Rathnam Mattapalli as EVP & Group CFO — implying a second handoff in roughly six months. Three other pre-listing director resignation letters (Sanjeev Lakra, Smita V Nair) are posted on the IR site.
(Sources: ETCFO 4 Nov 2025; bwcfoworld.com; Yahoo Finance executive list; sagility.com IR.)
5. Q4 FY26: in-line print, but stock fell 4.2% on margin and US-payer commentary
Q4 FY26: Revenue $216M (+29% YoY in INR, +19.4% CC); Adj EBITDA $53.7M (24.9% margin); Adj PAT $32.7M (+28%); reported net profit $27.5M (+41.2%). $30.7M new ACV across 18 clients. Despite the beat, the stock fell 4.2% to $0.45 on 12 May 2026 with 26.9M shares traded, after CEO commentary cited a "challenging US healthcare payer/provider environment." FY27 guidance: low double-digit constant-currency revenue growth; 24–25% adj EBITDA margin; complete debt repayment by end FY27. (Sources: whalesbook.com 12 May 2026; tradealone.com; in.investing.com.)
6. Analyst consensus: Buy, $0.58–$0.66 target — but MarketsMojo just downgraded to Hold
MarketScreener consensus: 9–10 analysts, avg target $0.66 (range $0.58–$0.73; high $0.77 per Alpha Spread). Trendlyne: 5 analysts, avg $0.63, implied +47% upside from ~$0.43. Nomura initiated Buy at $0.58 (later $0.61); Jefferies Buy maintained, target $0.57 → $0.65 (Oct 30, 2025) after a January peak of $0.75; Kotak Buy at $0.55; ICICI Buy at $0.63. MarketsMojo downgraded Buy → Hold on 29 May 2026 citing mixed technical/valuation signals.
(Sources: marketscreener.com; trendlyne.com; tradebrains.in 27 Mar 2026; moneycontrol.com SIL27; marketsmojo.com 29 May 2026.)
7. Industry positioning solid — Everest Group Leader and NelsonHall Leader in 2026
Everest Group Healthcare Payer Intelligent Operations PEAK Matrix 2026 named Sagility a Leader (one of 33 evaluated providers), citing investments in Sagility Synchrony, SmarTec, and Sagi360 platforms. NelsonHall NEAT 2026 (Quality, Risk & Performance Management) likewise named Sagility a Leader, citing "AI-enabled pattern detection to support real-time audit." Both rankings position Sagility favorably vs diversified competitors (TCS, Infosys, Cognizant, Accenture, Genpact, EXL, WNS, Firstsource). (Sources: prweb.com 4 Mar 2026; sagility.com press release 19 Mar 2026.)
8. BroadPath cross-sell narrative is faltering
Q3 FY26 transcript (28 Jan 2026): "Cross sell into Broadpath was limited this quarter as payers were primarily focused on the AEP season." Management deferred conversion to post-AEP — but no named cross-sell deal has been announced. This is a credibility flag on the mid-market diversification thesis just as the second EQT sell-down was executed.
BroadPath was acquired 30 Jan 2025 for $58M (0.83x revenue), adding 1,600 employees and 30+ clients with a $70M revenue footprint in 2024. (Sources: alphastreet.com Q3 transcript; vccircle.com 30 Jan 2025.)
9. Customer concentration: ICRA confirms top-3 ≈ 65%, top-5 ≈ 78% of revenue
ICRA's October 2024 rating rationale and the September 2025 update consistently document that the top 3 customers = ~65% of revenue and top 5 = 78% in FY25, with 100% of revenue from US healthcare. Clients are not publicly identified — though Sagility states it serves "six of the top ten U.S. payers" and Optum is listed as a Capability Partner in its partner ecosystem, suggesting UnitedHealth Group adjacency. (Sources: icra.in rating rationale 9 Oct 2024 and 2025 update; sagility.com partner ecosystem.)
10. The forensic file is clean — but the SAR overhang and tax notice deserve attention
Searches surfaced no short-seller report, no SEBI/SEC probe, no auditor resignation, no material weakness, no restatement post-IPO, no FCPA action. Auditor Section 143(12) report is clean.
What did surface: (i) Jefferies Dec 2024 note flagged Share Appreciation Rights (SAR) compressing reported EBITDA margin ~230 bps in FY25; SAR is treated as "non-cash" in adjusted EBITDA but parent-level settlement and listed-entity dilution are not disclosed. (ii) Income tax demand was revised on 19 May 2026 from $10.5M to $6.0M — a 43% reduction following a rectification order. (iii) Auditors disclosed 13 sexual-harassment complaints in FY26 (11 disposed, 5 pending >90 days) — non-trivial for a 46,000-employee BPM. (Sources: BusinessToday Jefferies note 20 Dec 2024; marketscreener.com 18 May 2026; IIFL Directors' Report.)
Recent News Timeline
What the Specialists Asked
Governance and People Signals
Promoter holding has been absorbed primarily by domestic mutual funds (8.3% → 14.5%) and FIIs (6.0% → 10.0%), with the FII investor count expanding from 199 to 223. This is constructive sponsorship quality, not passive disinterest. (Sources: trendlyne.com Mar 2026 snapshot; upstox.com SAGILITY shareholding 5 Jun 2026.)
Pledge flag: MarketsMojo discloses that 100% of remaining promoter shares are pledged. Combined with the IPO disclosure that Sagility B.V. shares are pledged against external financing, a default event could trigger change-of-control — a structural overhang larger than the OFS history alone suggests.
Management profile
CEO Ramesh Gopalan (b. 1968, IIT Dhanbad / IIM Ahmedabad) — directly carried over from HGS where he ran the global healthcare business; Glassdoor CEO approval 89%. CFO turnover: Sarvabhouman Srinivasan (in since Jan 2022) resigned Nov 2025; Abhishek Kayan appointed Deputy CFO; Srinivas Rathnam Mattapalli now seated as EVP & Group CFO by Q4 FY26. Independent director William Winkenwerder Jr (former US Asst Secretary of Defense for Health Affairs) is the standout healthcare credential. EQT representative Jimmy Mahtani sits on the board.
CEO compensation FY ending Dec 2025: $0.76M (Yahoo Finance). US-side leadership comp benchmarks (Salary.com): Chief Growth Officer ~$432K, EVP & General Counsel ~$337K. Glassdoor: 4.1/5 overall (1,220 reviews), 82% recommend, 82% positive business outlook; common cons are "low pay vs workload" and "metrics-focused TLs." Headcount 48,522 (Q4 FY26); attrition 26.6% (Q1 FY26) with a spike in Q4 voluntary attrition flagged on the call.
Industry Context
The healthcare BPM landscape has been reshaped by the Capgemini–WNS deal (16.3x EV/EBITDA strategic premium for an Agentic-AI-enabled BPS pure-play) — establishing Sagility as one of the few remaining listed vertical pure-plays. Listed Indian healthcare-services peers IKS (Inventurus Knowledge Solutions, $2.9B mkt cap, ~39x P/E) and Indegene ($1.3B, ~28x) are the cleanest direct comps; all three have underperformed since CY25 listing (IKS -13% YTD, Sagility -21%, Indegene -22% per Mint). Larger diversified competitors (TCS, Infosys, Cognizant, Accenture, Genpact, EXL, Firstsource) are present but not pure-plays.
Regulatory tailwinds: US healthcare ops spend reached ~$101.1B in 2023 (per Sagility RHP); Sagility's ~1.23% share leaves long runway. CMS rules increasingly require human-in-loop clinical decisions — a structural moat for Sagility's high-value member engagement revenue.
Regulatory headwinds: The HIRE Act (Sen. Moreno, 5 Sep 2025) — a 25% offshoring excise tax — remains alive but unscheduled for vote; tax press (MGO CPA Dec 2025, Cullen & Dykman Oct 2025) describes prospects as "unclear." Quantified margin impact would be material; carries it as a binary watch-item into FY27.
AI dynamic: Both threat (per-transaction rate deflation cited by JM Financial 20 May 2026; Nifty IT -13% YTD) and offense (18 AI use cases live across 8 clients; ~40% manual-effort reduction). Sagility appears better-positioned than diversified peers to navigate this — but the deflation overhang is real and likely to compress headline growth over the next ~12 months.